Skip to main content
. 2022 Jul 11;150(4):796–805. doi: 10.1016/j.jaci.2022.05.029

Fig 3.

Fig 3

Inflammatory activation in patients with COVID-19. A, Concentration of the inflammatory cytokine IL-6, IL-18, and IL-1β, and chemokines CXCL9 and IP-10, measured by BD CBA assays and ELISA kit for Human Soluble Protein and peripheral blood type I interferon score measured by quantitative PCR in patients with COVID-19 before and after treatment with anakinra. Dashed lines represent the mean + 2 SD of HD control values. B, Serum secretion of IL-18 and IL-1β at day 0 in patients affected by severe COVID-19. CXCL9, CXC motif chemokine ligand 9; HD, healthy control; IP-10, CXC motif chemokine ligand 10. ∗P < .05, ∗∗P < .01 as assessed by Mann-Whitney t test.